The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
Tislelizumab is an anti-PD-1 monoclonal antibody with high binding affinity for PD-1 and with
minimized Fcγ receptor binding on macrophages. Regorafenib has been approved in mCRC by CFDA.
Hepatic arterial infusion chemotherapy has a high local control rate for liver metastases.
NCCN guidelines and several expert consensus recommend that regional hepatic arterial
infusion chemotherapy can be considered as a "rescue treatment" for patients with colorectal
cancer liver metastases who fail to receive first-line or second-line systemic chemotherapy,
which can significantly prolong the overall survival of patients.